Transparency
Source library
This is the complete record of sources behind our content. Each entry lists study design, peer-review status, disclosed funding, and the limitations we noted when we read it. We publish the sources we could not yet verify as openly as the ones we could — those records are held back from citation until verification is complete.
- Verified & citable
- 50
- Awaiting verification
- 0
Sources
Every source below was reviewed directly. Study design, peer-review status, and stated limitations are listed so you can weigh each one yourself.
American Academy of Dermatology Association
- Clinical guideline
- Not peer-reviewed
- Strong clinical evidence
Consumer-facing guidance from the American Academy of Dermatology describing male pattern hair loss, its typical progression from the hairline and crown, its hereditary and androgen-related basis, and the treatment options dermatologists commonly discuss.
Limitations: This is patient-education material rather than a systematic review. It summarises professional consensus without reporting the underlying study data, effect sizes, or confidence intervals, so it cannot be used to support a specific quantitative outcome.
Accessed 2026-08-17
American Academy of Dermatology Association
- Clinical guideline
- Not peer-reviewed
- Strong clinical evidence
Describes how dermatologists evaluate hair loss, including history, scalp examination, pull tests, blood work, and biopsy, and outlines the categories of treatment used depending on the diagnosis.
Limitations: Patient-education material. It does not quantify treatment response rates and does not replace the full clinical guideline literature for any individual therapy.
Accessed 2026-08-17
American Academy of Dermatology Association
- Clinical guideline
- Not peer-reviewed
- Strong clinical evidence
Dermatologist guidance on washing, drying, brushing, heat styling, and chemical treatment practices that reduce mechanical and thermal damage to the hair fiber.
Limitations: Practical consensus advice. Individual recommendations are not each tied to controlled trial evidence, and the guidance addresses fiber condition rather than follicle biology or density.
Accessed 2026-08-17
National Institutes of Health, Office of Dietary Supplements
- Government / regulatory
- Not peer-reviewed
- Moderate clinical evidence
Authoritative review of biotin intake, status assessment, deficiency, and supplementation. States that biotin deficiency is rare in people eating a varied diet and that evidence does not support biotin supplementation for hair or nail growth in people who are not deficient. Also notes that high-dose biotin can interfere with some laboratory immunoassays.
Limitations: A narrative expert review rather than a meta-analysis. It summarises the state of evidence and does not itself report new trial data.
Accessed 2026-08-17
National Institutes of Health, Office of Dietary Supplements
- Government / regulatory
- Not peer-reviewed
- Strong clinical evidence
Reviews iron requirements, deficiency, assessment, groups at risk, supplementation, upper intake levels, and the risks of excess iron, including the narrow margin between adequacy and overload in adult men.
Limitations: Addresses iron status generally rather than hair outcomes specifically. It does not establish that correcting iron status changes hair density in people with normal iron levels.
Accessed 2026-08-17
National Institutes of Health, Office of Dietary Supplements
- Government / regulatory
- Not peer-reviewed
- Moderate clinical evidence
Reviews zinc physiology, dietary sources, deficiency signs including hair loss in frank deficiency, assessment difficulties, interactions with copper absorption, and tolerable upper intake levels.
Limitations: Deficiency-focused. It does not support supplementation above requirements for hair benefit, and notes that reliable assessment of marginal zinc status is difficult.
Accessed 2026-08-17
National Institutes of Health, Office of Dietary Supplements
- Government / regulatory
- Not peer-reviewed
- Limited or mixed clinical evidence
Describes how multivitamin and mineral products are regulated and formulated in the United States, the wide variation in composition between products, and the mixed evidence on health outcomes from broad supplementation.
Limitations: Because product composition varies so widely, findings for one multivitamin formula cannot be generalised to another. The fact sheet does not evaluate hair-specific formulations.
Accessed 2026-08-17
U.S. Food and Drug Administration
- Government / regulatory
- Not peer-reviewed
Explains the difference between permitted structure/function claims and prohibited disease claims for dietary supplements, and the required disclaimer stating that the statements have not been evaluated by the FDA.
Limitations: A regulatory explanation, not scientific evidence. It defines what a company may say; it says nothing about whether a particular product works.
Accessed 2026-08-17
U.S. Food and Drug Administration, 2008
- Government / regulatory
- Not peer-reviewed
Sets out the FDA's thinking on what constitutes competent and reliable scientific evidence to substantiate a dietary supplement structure/function claim, including the relevance of the studied population, dose, and product form to the claim being made.
Limitations: Non-binding guidance. It describes the agency's current thinking rather than a fixed legal standard.
Accessed 2026-08-17
U.S. Federal Trade Commission
- Government / regulatory
- Not peer-reviewed
Explains prohibitions on fake or misleading consumer reviews and testimonials, undisclosed insider reviews, and misrepresenting a company-controlled review site as independent.
Limitations: Business guidance summarising a rule. It is not a substitute for the rule text or for legal advice.
Accessed 2026-08-17
U.S. Federal Trade Commission, 2022
- Government / regulatory
- Not peer-reviewed
Describes the substantiation the FTC expects for health-related advertising claims, how qualifying language is evaluated in the context of a whole advertisement, and how the net impression of an advertisement is assessed rather than isolated disclaimers.
Limitations: Advertising-law guidance. It does not evaluate any specific ingredient or product.
Accessed 2026-08-17
- [12]
Hair Loss
MedlinePlus, U.S. National Library of Medicine
- Government / regulatory
- Not peer-reviewed
- Strong clinical evidence
Government health-information overview of hair problems and hair loss, including common causes such as heredity, hormonal change, medical conditions, medications, and physical or emotional stress, and when medical evaluation is appropriate.
Limitations: A consumer overview that links to other resources rather than reporting primary data.
Accessed 2026-08-17
Journal not yet confirmed, 2025
- Mechanistic research
- Peer-reviewed
Named in the build blueprint as a peer-reviewed framework paper arguing for a multifactorial, holistic model of managing hair aging. The record exists so the citation can be wired up, but the article has not been retrieved or read.
Limitations: Bibliographic details, journal, authorship, DOI, and content have not been verified by this build. Nothing may be attributed to this paper until a team member supplies the DOI or PMID and the article is read.
Funding and conflicts: Funding and author conflict disclosures not yet reviewed.
Accessed 2026-08-17
Journal not yet confirmed, 2026
- Mechanistic research
- Peer-reviewed
Named in the build blueprint as a peer-reviewed framework paper proposing an integrative model for hair longevity management. The record exists so the citation can be wired up, but the article has not been retrieved or read.
Limitations: Bibliographic details, journal, authorship, DOI, and content have not been verified by this build. Nothing may be attributed to this paper until a team member supplies the DOI or PMID and the article is read.
Funding and conflicts: Funding and author conflict disclosures not yet reviewed.
Accessed 2026-08-17
U.S. Food and Drug Administration
- Government / regulatory
- Not peer-reviewed
- Strong clinical evidence
Placeholder for the current FDA labeling for over-the-counter topical minoxidil, which is the authoritative source for approved use, directions, warnings, and adverse reactions.
Limitations: The exact label document and revision date have not been pinned. Drug pages must cite the specific current label, not the Drugs@FDA search index.
Accessed 2026-08-17
U.S. Food and Drug Administration
- Government / regulatory
- Not peer-reviewed
- Strong clinical evidence
Placeholder for the current FDA prescribing information for finasteride 1 mg, which is the authoritative source for approved indication, mechanism, clinical trial results, warnings, and adverse reactions.
Limitations: The exact label document and revision date have not been pinned. Any statement about efficacy, adverse effects, or sexual side-effect rates must come from the current label or a qualifying peer-reviewed source.
Accessed 2026-08-17
Leonard C. Sperling. Journal of the American Academy of Dermatology, 1991. doi:10.1016/0190-9622(91)70167-Z
- Reference work
- Peer-reviewed
Clinical review of normal hair follicle and shaft anatomy, including structures used in diagnosis.
Limitations: A narrative review published in 1991; terminology and methods have continued to evolve.
Accessed 2026-08-19
Aishi Liang, Yingshan Fang, Lan Ye, et al. Frontiers in Cell and Developmental Biology, 2023. doi:10.3389/fcell.2023.1278278
- Reference work
- Peer-reviewed
Reviews biological pathways associated with greying, thinning, follicle aging, and shaft changes.
Limitations: Much of the mechanistic evidence comes from laboratory or animal models rather than treatment trials in people.
Accessed 2026-08-19
Rohan R. Shah, Jorge Larrondo, Thomas Dawson, et al. Archives of Dermatological Research, 2024. doi:10.1007/s00403-024-03235-2
- Reference work
- Peer-reviewed
Reviews the scalp microbial community and its possible relationships with scalp disorders and treatment.
Limitations: Associations between microbes and scalp conditions do not by themselves establish cause or prove that changing the microbiome improves hair growth.
Accessed 2026-08-19
Mrinal Gupta, Venkataram Mysore. Journal of Cutaneous and Aesthetic Surgery, 2016. doi:10.4103/0974-2077.178536
- Reference work
- Peer-reviewed
Reviews common systems used to describe the distribution and severity of patterned hair loss.
Limitations: Classification scales describe visible patterns; they do not identify the cause of hair change or predict an individual's response to treatment.
Accessed 2026-08-19
Ulrike Blume-Peytavi, A. Blumeyer, Antonella Tosti, et al. British Journal of Dermatology, 2011. doi:10.1111/j.1365-2133.2010.10011.x
- Clinical guideline
- Not peer-reviewed
Provides consensus guidance for evaluating suspected androgenetic alopecia and distinguishing it from other causes.
Limitations: This is an S1 expert-consensus guideline, and newer diagnostic tools and evidence may not be represented.
Accessed 2026-08-19
American Academy of Dermatology Association. American Academy of Dermatology Association, 2022
- Clinical guideline
- Not peer-reviewed
Patient guidance explaining why identifying the cause of hair loss is important and what a dermatologist may assess.
Limitations: Public-facing society guidance summarizes practice and does not provide the detail of a systematic clinical guideline.
Accessed 2026-08-19
- [23]
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis
Areej Adil, Marshall Godwin. Journal of the American Academy of Dermatology, 2017. doi:10.1016/j.jaad.2017.02.054
- Systematic review
- Peer-reviewed
Meta-analysis of randomized trials found minoxidil, finasteride, and low-level light therapy superior to placebo for selected androgenetic alopecia outcomes.
Limitations: Most pooled analyses had high heterogeneity, and the review did not establish that the options are interchangeable for every patient.
Accessed 2026-08-19
Aditya K. Gupta, Andrew Charrette. SKINmed, 2015
- Systematic review
- Peer-reviewed
Synthesizes placebo-controlled evidence for topical minoxidil in androgenetic alopecia.
Limitations: Included trials varied in formulation, concentration, duration, and outcome measurement.
Accessed 2026-08-19
U.S. Food, Drug Administration. U.S. Food and Drug Administration, 2003
- Government / regulatory
- Not peer-reviewed
FDA-approved OTC label describing the indicated use, expected time horizon, continued-use requirement, and warnings for a 5% topical minoxidil product.
Limitations: The label applies to a specific approved product and population, and it notes that it might not be the latest labeling.
Accessed 2026-08-19
José Manuel Mella, María Clara Perret, Matías Manzotti, et al. Archives of Dermatology, 2010. doi:10.1001/archdermatol.2010.256
- Systematic review
- Peer-reviewed
Reviews randomized evidence on finasteride efficacy and adverse effects in androgenetic alopecia.
Limitations: Trial reporting and follow-up may not capture all uncommon or delayed adverse effects.
Accessed 2026-08-19
U.S. Food, Drug Administration. U.S. Food and Drug Administration, 2014
- Government / regulatory
- Not peer-reviewed
FDA prescribing information covering indication, contraindications, warnings, adverse reactions, and clinical studies for finasteride in men with male pattern hair loss.
Limitations: The label is product-specific and dated 2014; current prescribing information and individual clinical context should be checked.
Accessed 2026-08-19
Suparuj Lueangarun, Poom Visutjindaporn, Yardnapar Parcharoen, et al. Journal of Clinical and Aesthetic Dermatology, 2021
- Systematic review
- Peer-reviewed
Reviews randomized trials of selected cleared home-use low-level light devices for pattern hair loss.
Limitations: Device designs, light parameters, treatment schedules, study sizes, and follow-up differed, limiting generalization to every device.
Accessed 2026-08-19
U.S. Food, Drug Administration. U.S. Food and Drug Administration, 2014
- Government / regulatory
- Not peer-reviewed
FDA 510(k) summary documenting substantial-equivalence clearance for one low-level light device and its stated indications.
Limitations: 510(k) clearance is device-specific and is not the same as FDA drug approval or proof that all consumer light devices are effective.
Accessed 2026-08-19
- [30]
Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis
Adam G. Evans, James M. Mwangi, Rand W. Pope, et al. Journal of Dermatological Treatment, 2022. doi:10.1080/09546634.2020.1770171
- Systematic review
- Peer-reviewed
Systematic review and meta-analysis of PRP studies reporting changes in hair density and thickness for androgenetic alopecia.
Limitations: Preparation methods and treatment protocols varied substantially, and the authors called for lower-bias trials and standardized protocols.
Accessed 2026-08-19
Sergio Vano-Galvan, Christian N. Bisanga, P. Bouhanna, et al. Journal of Dermatological Treatment, 2023. doi:10.1080/09546634.2023.2232065
- Clinical guideline
- Not peer-reviewed
International Delphi consensus on assessment and care before and after hair transplantation.
Limitations: Expert consensus is useful where trials are sparse but does not replace comparative randomized evidence.
Accessed 2026-08-19
Hind M. Almohanna, Azhar A. Ahmed, John P. Tsatalis, et al. Dermatology and Therapy, 2019. doi:10.1007/s13555-018-0278-6
- Reference work
- Peer-reviewed
Reviews evidence connecting selected vitamin and mineral deficiencies or excesses with non-scarring hair loss.
Limitations: The evidence is uneven across nutrients, and associations do not show that supplements help people who are not deficient.
Accessed 2026-08-19
National Institutes of Health Office of Dietary Supplements. National Institutes of Health, 2022
- Government / regulatory
- Not peer-reviewed
Summarizes biotin requirements, evidence for hair claims, safety, and interference with laboratory tests.
Limitations: This is a nutrient fact sheet, not a trial of biotin for common male pattern hair loss.
Accessed 2026-08-19
National Institutes of Health Office of Dietary Supplements. National Institutes of Health, 2025
- Government / regulatory
- Not peer-reviewed
Summarizes iron physiology, recommended intake, deficiency, excess, and medication interactions.
Limitations: The fact sheet addresses general nutrition and safety; it does not establish iron as a treatment for hair loss without confirmed deficiency.
Accessed 2026-08-19
Yoonhee Lee, Youn-Duk Kim, Hye-Jin Hyun, et al. Annals of Dermatology, 2011. doi:10.5021/ad.2011.23.4.455
- Observational study
- Peer-reviewed
Laboratory study found greater surface damage to hair fibers as dryer temperature increased.
Limitations: The experiment used standardized hair samples and does not directly measure long-term clinical breakage or follicle health in daily life.
Accessed 2026-08-19
Amit B. Kumar, Divya Shamim Holla, and B. M. Prasanna Kumar. International Journal of Trichology, 2018. doi:10.4103/ijt.ijt_47_18
- Reference work
- Peer-reviewed
Reviews proposed mechanisms, associations, evaluation, and limited treatment evidence for premature hair greying.
Limitations: Evidence for interventions is sparse and often based on small or uncontrolled studies.
Accessed 2026-08-19
Enza Cestone, Eleonora Sparta, Vincenzo Nobile, et al. Journal of Cosmetology & Trichology, 2023. doi:10.37421/2471-9323.2023.9.207
- Randomized trial
- Peer-reviewed
A six-month randomized, double-blind, placebo-controlled trial in 86 men with mild-to-moderate androgenetic alopecia reported favorable changes in hair density and growth-cycle measures with 250 mg daily of a standardized black-rice and prickly-pear-flower blend.
Limitations: This is one branded-ingredient study, manufacturer and contract-research affiliations are relevant, reporting does not establish effectiveness of every formula containing the ingredient, and independent replication is needed.
Accessed 2026-08-19
Torsten Grothe, Franziska Wandrey, and Cornelia Schuerch. Phytotherapy Research, 2020. doi:10.1002/ptr.6528
- Observational study
- Peer-reviewed
A short communication reported a 10-person topical gene-expression study and a 21-person oral pilot in which 100 mg daily of pea sprout extract was associated with reduced collected shed hairs over eight weeks.
Limitations: The oral study was small and exploratory, the report does not describe a placebo-controlled oral comparison, the authors were affiliated with the ingredient supplier, and the findings require independent confirmation.
Accessed 2026-08-19
Young Hye Cho, Sang Yeoup Lee, Dong Wook Jeong, et al. Evidence-Based Complementary and Alternative Medicine, 2014. doi:10.1155/2014/549721
- Randomized trial
- Peer-reviewed
A 24-week randomized, double-blind, placebo-controlled trial in 76 men with mild-to-moderate androgenetic alopecia reported more favorable hair-count and self-assessment outcomes with a specific 400 mg pumpkin seed oil preparation.
Limitations: This was a single modest-sized study of a specific preparation; replication is limited, the mechanism was not established clinically, and the result cannot be generalized to all pumpkin products or multi-ingredient formulas.
Accessed 2026-08-19
Evyatar Evron, Margit Juhasz, Arash Babadjouni, et al. Skin Appendage Disorders, 2020. doi:10.1159/000509905
- Systematic review
- Peer-reviewed
A systematic review found signals of benefit across small studies of oral and topical saw-palmetto-containing interventions for several hair-loss presentations.
Limitations: The products, routes, populations, and outcomes varied, robust high-quality data were lacking, and the contribution and long-term safety of saw palmetto alone remained uncertain.
Accessed 2026-08-19
Deo Nidhi Mishra, Manoj Kumar. Heliyon, 2024. doi:10.1016/j.heliyon.2024.e36885
- Randomized trial
- Peer-reviewed
A 60-day randomized placebo-controlled trial in 60 adults with high stress evaluated 60 mg and 120 mg of a standardized ashwagandha extract and reported favorable stress, cortisol, and male testosterone outcomes.
Limitations: The study was short, selected participants for high stress, did not measure hair outcomes, and therefore supports stress and vitality endpoints rather than hair-density or hair-growth claims.
Accessed 2026-08-19
U.S. Food, Drug Administration. U.S. Food and Drug Administration, 2024
- Government / regulatory
- Not peer-reviewed
FDA guidance explains the distinction between dietary-supplement structure/function claims, general well-being claims, nutrient-deficiency claims, and disease claims.
Limitations: This is regulatory guidance about permissible claim categories and substantiation, not evidence that a particular dietary supplement is effective.
Accessed 2026-08-19
Organon LLC; U.S. National Library of Medicine DailyMed. DailyMed, U.S. National Library of Medicine, 2024
- Government / regulatory
- Not peer-reviewed
Current U.S. prescribing information for Propecia covering its indication, warnings, clinical-trial adverse-event rates, postmarketing reports, reproductive considerations, and patient counseling.
Limitations: The information is product- and dose-specific. Trial rates may not predict an individual's experience or compare directly with another intervention, and voluntary postmarketing reports cannot reliably establish frequency or causality.
Accessed 2026-08-19
Lei Zhou, Wenkang Zhu, and Yan Chen. Frontiers in Nutrition, 2026. doi:10.3389/fnut.2025.1719711
- Systematic review
- Peer-reviewed
A network meta-analysis of 19 randomized trials and 1,658 participants reported positive signals for selected oral supplement interventions across hair-density and physician-rated outcomes.
Limitations: Products and doses varied, most comparisons were indirect, heterogeneity and publication bias were present, long-term safety data were limited, and the authors said the evidence was insufficient for direct regimen selection.
Accessed 2026-08-19
Lara Drake, Sophia Reyes-Hadsall, Jeremy Martinez, et al. JAMA Dermatology, 2023. doi:10.1001/jamadermatol.2022.4867
- Systematic review
- Peer-reviewed
A systematic review of 30 studies, including 17 randomized trials, found potential benefit from several nutritional interventions in people with hair loss who were not selected for a known baseline nutritional deficiency; reported adverse effects were generally rare and mild in the included studies.
Limitations: Products, diagnoses, comparators, outcomes, study quality, and industry involvement varied, so the review does not establish that every supplement works or that a selected ingredient proves the effectiveness of a different finished formula.
Accessed 2026-08-26
Mariana Alvares Penha, Helio Amante Miot, Michal Kasprzak, et al. JAMA Dermatology, 2024. doi:10.1001/jamadermatol.2024.0284
- Randomized trial
- Peer-reviewed
A 24-week randomized double-dummy trial in 90 men with androgenetic alopecia did not show oral minoxidil 5 mg to be superior to topical minoxidil 5% on the primary density comparisons, illustrating that oral route alone does not determine effectiveness.
Limitations: The trial was conducted at one center, was relatively small, had substantial follow-up loss, evaluated one oral dose and one topical regimen, and does not compare supplements with topical therapies.
Accessed 2026-08-26
Maria Fernanda Reis Gavazzoni Dias, Aline Loures, and Chloe Ekelem. Indian Journal of Plastic Surgery, 2021. doi:10.1055/s-0041-1739241
- Reference work
- Peer-reviewed
Reviews how shampoos, conditioners, camouflage products, dyes, straighteners, and other cosmetics affect scalp care, fiber friction, manageability, breakage, appearance, and adherence in people with hair loss.
Limitations: This is a narrative review of varied cosmetic products and mechanisms; cosmetic fiber benefits do not establish new follicle growth or treatment of androgenetic alopecia.
Accessed 2026-08-26
Francisco Jimenez, Majid Alam, James E. Vogel, et al. Journal of the American Academy of Dermatology, 2021. doi:10.1016/j.jaad.2021.03.124
- Reference work
- Peer-reviewed
Reviews modern follicular-unit transplantation, donor anatomy, candidacy, harvesting techniques, surgical planning, and limitations of the finite donor supply.
Limitations: A clinical overview cannot estimate an individual result, recovery course, scar visibility, complication risk, graft survival, or total price, all of which vary with candidate and surgeon.
Accessed 2026-08-26
American Academy of Dermatology Association. American Academy of Dermatology Association, 2026
- Systematic review
- Not peer-reviewed
Consumer clinical guidance describes common male pattern hair-loss options and states that finasteride has been shown to slow further loss in about 80% to 90% of men taking it.
Limitations: This is a consumer guidance page rather than a primary trial or product label, and the summary percentage does not replace a review of population, endpoint, duration, adverse effects, and current prescribing information.
Accessed 2026-08-26
Michael G. Davis, Melissa P. Piliang, Wilma F. Bergfeld, et al. International Journal of Cosmetic Science, 2021. doi:10.1111/ics.12734
- Randomized trial
- Peer-reviewed
A 24-week randomized trial in adults with self-perceived thinning reported reduced shedding, higher total hair count, and improved scalp-barrier measures for a defined antioxidant shampoo and leave-on regimen versus its control formulation.
Limitations: The study tested one multi-product cosmetic regimen, was funded by Procter & Gamble, included company-affiliated authors, and does not validate all shampoos, scalp serums, individual ingredients, or treatment of androgenetic alopecia.
Accessed 2026-08-26